TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06300593

Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement and comparison of leucocytosis and concentrations of C-reactive protein (CRP), interleukin-1 (IL-1), IL-6, IL-10, Tumor Necrosis Factor (TNF-alpha) in PCOS phenotypes A, B, C and D
Description: A venous blood sample of approximately 10 ml will be collected in the morning after 8 hours of fasting to determine and compare the above parameters of peripheral blood in the four study arms

Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement and comparison of leucocytosis and concentrations of C-reactive protein (CRP), interleukin-1 (IL-1), IL-6, IL-10, Tumor Necrosis Factor (TNF-alpha) in PCOS phenotypes A, B, C and D
Description: A venous blood sample of approximately 10 ml will be collected in the morning after 8 hours of fasting to determine and compare the above parameters of peripheral blood in the four study arms

Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement and comparison of leucocytosis and concentrations of C-reactive protein (CRP), interleukin-1 (IL-1), IL-6, IL-10, Tumor Necrosis Factor (TNF-alpha) in PCOS phenotypes A, B, C and D
Description: A venous blood sample of approximately 10 ml will be collected in the morning after 8 hours of fasting to determine and compare the above parameters of peripheral blood in the four study arms

Intervention type: DIAGNOSTIC_TEST
Intervention: Evaluation of the correlation of serum concentrations of selected inflammatory markers (leucocytosis, CRP, IL-1, IL-6, IL-10, TNF-alpha) with metabolic and hormonal parameters
Description: A venous blood sample of approximately 10 ml will be collected in the morning after 8 hours of fasting to test the above correlations in the four study arms

Intervention type: DIAGNOSTIC_TEST
Intervention: Evaluation of the correlation of serum concentrations of selected inflammatory markers (leucocytosis, CRP, IL-1, IL-6, IL-10, TNF-alpha) with metabolic and hormonal parameters
Description: A venous blood sample of approximately 10 ml will be collected in the morning after 8 hours of fasting to test the above correlations in the four study arms
Study: NCT05652543

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCTV01E
Description: Participants will be vaccinated with SCTV01E on Day 0, and safety and immunogenicity will be monitored for 180 days after vaccination.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (normal saline)
Description: Participants will be vaccinated with Placebo (normal saline) on Day 0, and safety and immunogenicity will be monitored for 180 days after vaccination.
Study: NCT05100381

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dry needling
Description: The patients will be placed in a prone position with a pillow under their belly to accommodate lumbar lordosis. Two lengths of sterile, disposable, 0.30 mm x 75 mm and 0.30 mm x 50 mm solid filament needle (Tony, China) will be used in this study. The length of the needle for each participant will be selected based on the size of the participant. The needles will be inserted into the lumbar multifidus muscle, 1.5 - 2 cm lateral to the spinous process of two or three painful segments, perpendicular to lamina (after piercing the skin, needles are directed inferomedially). The needles will be inserted to obtain local twitch response, and this process will continue until no more local twitch response occurs in each session. Then the needles will be left in place for 20 minutes.
Study: NCT06300593

Intervention type: DIAGNOSTIC_TEST
Intervention: Evaluation of the correlation of serum concentrations of selected inflammatory markers (leucocytosis, CRP, IL-1, IL-6, IL-10, TNF-alpha) with metabolic and hormonal parameters
Description: A venous blood sample of approximately 10 ml will be collected in the morning after 8 hours of fasting to test the above correlations in the four study arms
Study: NCT05100381

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: sham (placebo) dry needling
Description: The sham dry needling method includes the insertion of the needles subcutaneously and no local twitch response will be obtained. The needles will be left in the place for 20 minutes.
Study: NCT05599438

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT06140771

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: 0.76% Sodium Monofluorophosphate Dentifrice
Description: Whole mouth brushing with a toothpaste, twice daily for the duration of the study.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: 1.15% Sodium Monofluorophosphate Dentifrice
Description: Whole mouth brushing with a toothpaste, twice daily for the duration of the study.
Study: NCT05599438

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT06326762

Intervention type: OTHER
Intervention: comparaison
Description: description indicate

Intervention type: OTHER
Intervention: comparaison
Description: description indicate
Study: NCT04901377

Intervention type: COMBINATION_PRODUCT
Intervention: Estradiol valerate/ Dienogest
Description: Combined hormonal contraceptive (combined oral contraceptives, COCs)
Study: NCT05508659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duvelisib
Description: Duvelisib PR2D bid po. until progressive disease (PD), unacceptable toxicity, or any criterion for withdrawal from the trial.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duvelisib
Description: Duvelisib PR2D bid po. until progressive disease (PD), unacceptable toxicity, or any criterion for withdrawal from the trial.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SG001
Description: 240mg, each two weeks,iv,until progressive disease (PD), unacceptable toxicity, or any criterion for withdrawal from the trial.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SG001
Description: 240mg, each two weeks,iv,until progressive disease (PD), unacceptable toxicity, or any criterion for withdrawal from the trial.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SG001
Description: 240mg, each two weeks,iv,until progressive disease (PD), unacceptable toxicity, or any criterion for withdrawal from the trial.
Study: NCT06140771

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.454% Stannous Fluoride Dentifrice
Description: Whole mouth brushing with a toothpaste, twice daily for the duration of the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.454% Stannous Fluoride Dentifrice
Description: Whole mouth brushing with a toothpaste, twice daily for the duration of the study.
Study: NCT05011487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: 80mg/qd oral for 60 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin (75mg/m2) to be administered with pemetrexed on Day 1 of every 3-week cycle for 2 cycles.
Study: NCT04088422

Intervention type: PROCEDURE
Intervention: peripheral blood collection
Description: peripheral blood collection at treatment start, interm PET/CT, end of treatment PET/CT, one-year and two-year follow-up and or progression or relapse
Study: NCT06387186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucine-Enriched Essential Amino Acid powder
Description: Leucine-Enriched Essential Amino Acid Powder will be orally/enterally administered by mixing in water or ketogenic formula.
Study: NCT05011487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed (500 mg/m2) to be administered with cisplatin on Day 1 of every 3-week cycle for 2 cycles
Study: NCT05957887

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: Assess the efficacy of Dapagliflozin on cardiac function and LV remodeling in acute ST elevation anterior myocardial infarction patients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: Assess the efficacy of Dapagliflozin on cardiac function and LV remodeling in acute ST elevation anterior myocardial infarction patients
Study: NCT06058988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: All participants will receive T-DXd prior to indicated brain tumor resection/biopsy
Study: NCT05963763

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Career Navigator Coaching
Description: The Career Navigator will support participants with a tailored approach to reach career and financial goals through one or more of the following services, in addition to referrals to other external services (community-based organizations) as needed for 6 months:~1. Career pathway navigation~2. Employee benefit maximization~3. Financial literacy and wealth building~4. Services funds for resources that mitigate specific barriers or needs.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Career Navigator Coaching
Description: The Career Navigator will support participants with a tailored approach to reach career and financial goals through one or more of the following services, in addition to referrals to other external services (community-based organizations) as needed for 6 months:~1. Career pathway navigation~2. Employee benefit maximization~3. Financial literacy and wealth building~4. Services funds for resources that mitigate specific barriers or needs.
Study: NCT05409287

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate Implant Loading
Description: A single implant crown will be mounted on the implant immediately after implant placement

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Early Implant Loading
Description: A single implant crown will be mounted on the implant 4 weeks after implant placement.
Study: NCT06370780

Intervention type: OTHER
Group type: OTHER
Intervention: EPI LOVE
Description: Observational cohort only
Study: NCT05621941

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Game-Supported Goal Management Training
Description: The investigational treatment is based on a compensatory strategy training named Goal Management Training (GMT). The investigational treatment will include GMT in combination with a compensatory strategy game which allows the patient to learn and apply the algorithm of GMT in a safe and controlled environment. This means that the multiple steps of the GMT will be learned during the treatment sessions under guidance of a therapist as well as in their own home environment by using the compensatory strategy game.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Information Group
Description: In the information group, patients are informed about non-specific consequences of acquired brain injury, aimed to increase patient's insight into their condition and with that improving functioning. The program consists of the following subjects: 1) cause of brain injury, 2) information processing and attention, 3) memory, 4) planning and performance, 5) fatigue, 6) changes in emotion and behavior and 7) processing and adjustments.
Study: NCT05165823

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sodium restriction
Description: Participants will be guided in minimizing sodium intake. Guidance will be both oral and written. Bread with low sodium content will be offered to the participants.
Study: NCT04869722

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Liquid Model
Description: Whey protein beverages will be used, with the amount of protein varied to study the effect on perception of the products (using sensory methods rating mouthdrying and discrimination tests 'which sample is more mouthdrying') all measured at home.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Solid Model
Description: Protein fortified scones will be used, with the amount of fat varied to study the effect on perception of the products (using sensory methods rating mouthdrying and discrimination tests 'which sample is more mouthdrying') all measured at home.
Study: NCT05329038

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated COVID-19 Vaccine
Description: 600SU inactivated virus in 0·5 mL of aluminium hydroxide solution per injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated COVID-19 Vaccine
Description: 600SU inactivated virus in 0·5 mL of aluminium hydroxide solution per injection
Study: NCT05138471

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation (tDCS)
Description: tDCS intervention will consist in placing two electrodes, the cathode on the supraorbital surface on the same side as the painful knee, and the anode on the parietal area, corresponding to the area of the primary motor cortex, on the opposite side. The intensity will be 2 milli amperes (mA) and stimulation will be 20 minutes. The placebo will generate an initial sensation, and then descend until the stimulation is turned off.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation (tDCS)
Description: tDCS intervention will consist in placing two electrodes, the cathode on the supraorbital surface on the same side as the painful knee, and the anode on the parietal area, corresponding to the area of the primary motor cortex, on the opposite side. The intensity will be 2 milli amperes (mA) and stimulation will be 20 minutes. The placebo will generate an initial sensation, and then descend until the stimulation is turned off.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS
Description: TENS intervention will consist in placing two electrodes on the sides of the patella of the affected knee. The frequency will be 10Herzts and the intensity will remain at a sensitive threshold level, without reaching the motor. The placebo will generate a sensation of current to descend to the minimum value that the equipment allows. Stimulation will last for 20 minutes.
Study: NCT05723445

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Glycemic Load Diet
Description: Food delivery service will provide a low glycemic load diet for 8 weeks, followed by a 4-month period of self-adherence to a low glycemic load diet with close nutritionist follow up
Study: NCT06340256

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continuous spinal anesthesia
Description: The Catheter will be then fed over the needle into the intrathecal space and Inserted 3cm cephalad into the subarachnoid space.The spinal needle and the modified Tuohy needle will be then removed, and a Luer connector and A filter previously filled with the anesthetic solution will be attached to the Catheter (priming volume 0.6ml). Plain bupivacaine 0.5% in 20ml vials will Be used CSA group received 1 ml(5 mg) of plain bupivacaine (0.5%) Together with fentanyl l25μg injected via the catheter at a rate of 0.2ml/15s. The level of the resulting sensory blockade will be tested using pin prick.
Study: NCT05138471

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise and General Education
Description: The General Education Intervention consisting in an educational program will be applied to all groups using audiovisual material to increase the subject's knowledge about his/her pathology, about chronic pain and recommendations for supervised exercise based on the NEMEX protocol for osteoarthritis (Ageberg et al.)18: the participants will be taught analytical strengthening exercises (quadriceps and hamstrings) and neuromuscular functional exercises (getting up from the chair or going up a step), with their detailed dosage (2 to 3 series with 10 to 15 repetitions) and a home follow-up model where the participant must record compliance with exercise as well as pain during activity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise and General Education
Description: The General Education Intervention consisting in an educational program will be applied to all groups using audiovisual material to increase the subject's knowledge about his/her pathology, about chronic pain and recommendations for supervised exercise based on the NEMEX protocol for osteoarthritis (Ageberg et al.)18: the participants will be taught analytical strengthening exercises (quadriceps and hamstrings) and neuromuscular functional exercises (getting up from the chair or going up a step), with their detailed dosage (2 to 3 series with 10 to 15 repetitions) and a home follow-up model where the participant must record compliance with exercise as well as pain during activity.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Exercise and General Education
Description: The General Education Intervention consisting in an educational program will be applied to all groups using audiovisual material to increase the subject's knowledge about his/her pathology, about chronic pain and recommendations for supervised exercise based on the NEMEX protocol for osteoarthritis (Ageberg et al.)18: the participants will be taught analytical strengthening exercises (quadriceps and hamstrings) and neuromuscular functional exercises (getting up from the chair or going up a step), with their detailed dosage (2 to 3 series with 10 to 15 repetitions) and a home follow-up model where the participant must record compliance with exercise as well as pain during activity.
Study: NCT05022511

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Screening status
Description: Women are offered check-up on screening status in both CCU and CRC screening. If a woman is not up to date in one or both screening programmes, she will be offered a self-sampling device and/or a FIT kit.
Study: NCT06340256

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continuous epidural anesthesia
Description: The needle is advanced until the epidural space is identified by the loss-of-resistance technique, and then a 20G catheter is inserted 3 cm cephalad into the epidural space. a test dose of 3ml of 2% lignocaine with adrenaline (1:200000) will be injected into the catheter. Three minutes later, 10 ml of plain bupivacaine (0.5%) together with fentanyl l50μg will be injected via the catheter.
Study: NCT06363305

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary capsules
Description: Daily doses of dietary capsaicin or placebo in capsule form

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Dietary capsules
Description: Daily doses of dietary capsaicin or placebo in capsule form
Study: NCT05918198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ven+CAG
Description: 100 mg on the first day, and then gradually increase to the target dose of 400 mg (100 mg d1, 200 mg d2, 400 mg d3) within 3 days; After that, the drug continued to be administered until the 14th day, 400 mg/day. When combined with CYP3A or P-gp inhibitors (mainly voriconazole in this study), adjust the venetoclax dose to 100 mg/day.~Ara-C 10mg/m2, ih, q12h × 14d； Acla 20mg/d × 4d； G-CSF 5ug/kg × 14d (WBC \> 30 × 10\^9/L pause)
Study: NCT05210595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg
Description: 75 mg/day as maintenance dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor 60mg
Description: In-hospital treatment with standard strategy ticagrelor 90mg twice daily, following de-escalation strategy ticagrelor 60 twice daily after discharge or post PCI 1 week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor 45 mg
Description: In-hospital treatment with standard strategy ticagrelor 90mg twice daily, following de-escalation strategy ticagrelor 45 twice daily after discharge or post PCI 1 week .
Study: NCT06156527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lazertinib
Description: Lazertinib 240mg, QD, daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lazertinib
Description: Lazertinib 240mg, QD, daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab Injectable Product
Description: Bevacizumab: 15mg/kg IV every 3 weeks
Study: NCT05266404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin/sitagliptin FDC
Description: Subjects will receive single dose of Dapagliflozin/sitagliptin FDC orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: Subjects will receive 100 mg single dose of Sitagliptin orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: Subjects will receive 10 mg single dose of Dapagliflozin orally.
Study: NCT05712486

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High force hip Lateral distraction
Description: Hip lateral distraction in adjusted position of maximun flexion and internal rotation, with neutral position of abduction/adduction applying high force of distraction.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Placebo force hip lateral distraction
Description: Hip lateral distraction in adjusted position of maximun flexion and internal rotation, with neutral position of abduction/adduction applying placebo force of distraction.
Study: NCT04768309

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ex vivo exploration of the effect of a probiotic over precursor indole production
Description: Fresh feces in chronic kidney patients and healthy volunteers will be collected. The feces will be instilled in artificial intestine with and without selected probiotics and production of uremic toxins will be measured.

Intervention type: OTHER
Group type: OTHER
Intervention: Ex vivo exploration of the effect of a probiotic over precursor indole production
Description: Fresh feces in chronic kidney patients and healthy volunteers will be collected. The feces will be instilled in artificial intestine with and without selected probiotics and production of uremic toxins will be measured.
Study: NCT04624620

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teaching Kitchen Collaborative Curriculum
Description: This is a referral-based teaching kitchen intervention that synergistically provides basic cooking skills, an evidence-based nutrition curriculum, mindfulness skills, activity tracking, and support for behavior change to augment weight management and lifestyle change in the primary care setting.
Study: NCT05487547

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IPL_RF_MGX
Description: intense pulsed light followed by Radiofrequency followed by meibomian gland expression
Study: NCT05206344

Intervention type: OTHER
Group type: OTHER
Intervention: clowns
Description: presence or absence of clowns during the performance of a painful act, on pain

Intervention type: OTHER
Group type: OTHER
Intervention: clowns
Description: presence or absence of clowns during the performance of a painful act, on pain
Study: NCT05136183

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HA-330 Disposable Hemoperfusion Cartridge (Jafron, China)
Description: * If no appropriate vascular access available, a double lumen catheter is placed by treating physicians, under ultrasonographic guidance.~* Two sessions of hemoperfusion using HA-330 Disposable Hemoperfusion Cartridge are performed 24 hours apart.~* Hemoperfusion is performed using either hemoperfusion or continuous renal replacement therapy machine. The optimal blood flow rate is 150-200 mL/min. The duration for each session in 2 hours. No systemic anticoagulant is given except for priming of the cartridge according to manufacturer recommendations.~* The first hemoperfusion session is recommended to be initiated within 12 hours after randomization.